CAS: 625-36-5; 3-Chloropropionyl Chloride

相似化合物

4635-59-0 15486-96-1

上下游产品

CAS号79-10-7 丙烯酸 | CAS号107-94-8 3-氯丙酸 | CAS号57-57-8 丙内酯 | CAS号676-83-5 甲基二氯膦 | CAS号15171-48-9 2-甲基-1,2-噁膦-5-酮... | CAS号79-03-8 丙酰氯 | CAS号75-44-5 光气 | CAS号54509-73-8 ethene | CAS号201230-82-2 carbon monoxide | CAS号107-13-1 丙烯腈 | CAS号111709-01-4 naphthalen-2-yl... | CAS号111550-38-0 1,1,5-trichloro... | CAS号347-93-3 3-氯-4'-氟苯丙酮 | CAS号3592-25-4 1,5-二氯-3-戊酮 | CAS号35999-20-3 3-氯-4'-甲氧基苯丙酮 | CAS号4600-86-6 5-叔丁基-1-茚满酮 | CAS号39494-07-0 3-chloro-N-(2,5... | CAS号542-76-7 β-氯丙腈 | CAS号35857-66-0 3-氯-1-(3,4-二氯苯基... | CAS号334504-88-0 3-Chloro-N-(2-e...

丙烯酸置于光气体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应 40.0H,反应生成 3-氯丙酰氯
参考文献:Stabilized Isocyanate Group-Containing Ethylenically Unsaturated Compound
标题:Stabilized Isocyanate Group-Containing Ethylenically Unsaturated Compound
摘要:本发明的一个目的是通过防止乙烯不饱和化合物中异氰酸酯基团的聚合,多聚反应和变色反应来提高其稳定性.本发明涉及一种用于含有异氰酸酯基团的乙烯不饱和化合物的稳定化组合物,包括:一种含有异氰酸酯基团和乙烯不饱和基团的乙烯不饱和化合物(a),其分子中包含一个或多个异氰酸酯基团和一个或多个乙烯不饱和基团;以及一种稳定剂(b),它是一种化合物,其中化合物(a)中的乙烯不饱和基团中的至少一个被取代为可能具有取代基的烷基卤素基团或氨基烷基基团.

专利信息

专利号:US-2004249170-A1
优先权日:2002-01-24
标 题 :Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
发明人：BORGHESE ALFIO
摘要:This invention provides a process for the synthesis of(S)-3-Methylamino-1-2-thienyl)-1-propanol, a key intermediate in the synthesis of duloxetine.

专利号:US-5973157-A
优先权日:1997-04-18
标题 :Process for the synthesis of 1,7-diarly or heteroaryl-heptane-4-ols and new synthetic intermediates
发明人：STIVANELLO MARIANO
权利人:FABBRICA ITALIANA SINTETICI SPA
摘要:This invention offers a process for the synthesis of a compound of the formula ##STR1## wherein R' is a phenyl, a substituted phenyl, a heterocyclic aromatic group, a heterocyclic aromatic substituted group, a linear or branched alkyl group, or a cycloalkyl group. n The invention also comprises the following compounds of a formula 1' and 2' as useful new synthesis intermediates. ##STR2## wherein R is a phenyl, a substituted phenyl, an alkyl, a cycloalkyl and X is Cl, Br, I, F, CH 3 SO 3 , p--CH 3 --C 6 H 4 --SO 3 .

专利号:US-5550267-A
优先权日:1994-06-14
标 题:Process for the synthesis of haloalkylferrocenes
发明人：GRAINDORGE HERVE; MONDET JEAN-CLAUDE; VINCENT CHARLES-HENRY
权利人:POUDRES & EXPLOSIFS STE NALE
摘要:The present invention relates to a process for the synthesis of haloalkylferrocenes, comprising a first stage of reaction, in the presence of AlCl 3 as catalyst and in organic solvent medium, of a carboxylic acid halide or anhydride with ferrocene or an alkylferrocene. n After this stage, without prior isolation of the intermediate compound, a metal hydride is added to the reaction mixture. n The haloalkylferrocenes are particularly useful as intermediates in the synthesis of combustion catalysts for propellants.

专利号:EP-2644590-A1
优先权日:2012-03-30
标 题:Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
权利人:LEK PHARMACEUTICALS
摘要:The present invention relates to the field of organic synthesis and describes the synthesis of specific intermediates suitable for the preparation of triazolopyrimidine compounds such as ticagrelor.

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-11198684-B2
优先权日:2017-07-28
标 题 :Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
发明人：OH SANG-HO; KHOO JA-HEOUK; LIM JONG-CHUL; LEE DOO-BYUNG; LEE JUNG-AE; LEE JUN-SUP; JU HYUN; SHIN WOO-SEOB; JEON SANG-SEOL
权利人:YUHAN CORP
摘要:The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.